Cholestatic Pruritus: Maralixibat Study

We are testing a new medication, maralixibat, for individuals with cholestatic pruritus to see if it can reduce itching and lower bile acid levels in the blood.

Confirmation phase (III)Post-Trial Drug AccessPartially RemoteStandard MedicinesOralDermatologyHepatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Maralixibat
Maralixibat is a substance that lowers bile acids to help relieve severe itching from liver-related bile buildup.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Hospital Femme Mere Enfant
Pediatric Gastroenterology, Hepatology and Nutrition
Bron, France
Bicetre Hospital
Pediatric hepato-gastro-enterology
Croulebarbe, France
Centre Hospitalier Regional De Marseille
Pediatric hepato-gastro-enterology
Marseille, France
Sponsor: Mirum Pharmaceuticals Inc.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.